You would certainly hope so Punk. Otherwise you'd start to wonder what hope there is for commercial exploitation (=shareholder added value) of Lupozor, the CNRS arrangement or the compounds in earlier stages of development with the current BOD.
They have some of the very best scientists and research facilities at their disposal through the collaborations with the CNRS and IECB - the sort of facilities and resources that most bios can only dream of. A very clever business model and you would hope and expect the research being carried out to yield results.
Time will tell of course but in the meantime am looking forward to finally seeing some news flow re. Lupuzor. We obviously should get details of European trial centres and investigators but thereafter I hope we get regular updates on recruitment. Will be interesting to see whether IMM keep shareholders informed of interim reviews too.
last ten seconds of interview "and we'll keep the market updated on the early stage portfolio too - there are some exciting developments there too"
Is there a chance that immupharma actually knew what they were doing when they made this deal?
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.